NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?-Case series and review of the literature

TY - JOUR

T1 - NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?-Case series and review of the literature

AU - Osumi, Hiroki

AU - Vecchione, Loredana

AU - Keilholz, Ulrich

AU - Vollbrecht, Claudia

AU - Alig, Annabel H S

AU - von Einem, Jobst C

AU - Stahler, Arndt

AU - Striefler, Jana K

AU - Kurreck, Annika

AU - Kind, Andreas

AU - Modest, Dominik P

AU - Stintzing, Sebastian

AU - Jelas, Ivan

N1 - Copyright © 2021 Elsevier Ltd. All rights reserved.

PY - 2021/8

Y1 - 2021/8

N2 - Upfront KRAS and NRAS gene testing ('RAS') is the standard of care for metastatic colorectal cancer (mCRC), to guide first-line treatment. The presence of RAS mutation (MT) is a negative predictor for the efficacy of anti-EGFR antibodies and the use of cetuximab and panitumumab is restricted to RAS wild-type (WT) mCRC. Conversion from RAS WT to RAS MT mCRC after treatment with anti-EGFR antibodies is a known and well-described acquired resistance mechanism. The by far less frequent 'NeoRAS wild-type' phenomenon (reversion from RAS MT to RAS WT) has recently drawn attention. The proposed effect of chemotherapy on RAS status in mCRC patients is not fully understood. Because of the intriguing biological consequence of a RAS MT to RAS WT reversion, subsequent treatment of NeoRAS WT patients with anti-EGFR antibodies is increasingly being discussed. Here, we report three clinical cases of NeoRAS WT mCRC patients, which received standard-of-care regimens for RAS MT mCRC. Anti-EGFR antibodies were used in two out of three patients after progression of the disease. One of the patients had a long-term response. In line with our observations, NeoRAS WT phenomenon occurs in clinical practice. Retesting of RAS status during treatment should be discussed in patients with unusual long-term clinical courses of RAS MT mCRC to optimise treatment strategy and to evaluate the use of anti-EGFR antibodies.

AB - Upfront KRAS and NRAS gene testing ('RAS') is the standard of care for metastatic colorectal cancer (mCRC), to guide first-line treatment. The presence of RAS mutation (MT) is a negative predictor for the efficacy of anti-EGFR antibodies and the use of cetuximab and panitumumab is restricted to RAS wild-type (WT) mCRC. Conversion from RAS WT to RAS MT mCRC after treatment with anti-EGFR antibodies is a known and well-described acquired resistance mechanism. The by far less frequent 'NeoRAS wild-type' phenomenon (reversion from RAS MT to RAS WT) has recently drawn attention. The proposed effect of chemotherapy on RAS status in mCRC patients is not fully understood. Because of the intriguing biological consequence of a RAS MT to RAS WT reversion, subsequent treatment of NeoRAS WT patients with anti-EGFR antibodies is increasingly being discussed. Here, we report three clinical cases of NeoRAS WT mCRC patients, which received standard-of-care regimens for RAS MT mCRC. Anti-EGFR antibodies were used in two out of three patients after progression of the disease. One of the patients had a long-term response. In line with our observations, NeoRAS WT phenomenon occurs in clinical practice. Retesting of RAS status during treatment should be discussed in patients with unusual long-term clinical courses of RAS MT mCRC to optimise treatment strategy and to evaluate the use of anti-EGFR antibodies.

KW - Circulating Tumor DNA/metabolism

KW - Colorectal Neoplasms/genetics

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Neoplasm Metastasis

KW - ras Proteins/genetics

U2 - 10.1016/j.ejca.2021.05.010

DO - 10.1016/j.ejca.2021.05.010

M3 - SCORING: Review article

C2 - 34153718

VL - 153

SP - 86

EP - 95

JO - EUR J CANCER

JF - EUR J CANCER

SN - 0959-8049

ER -